Hôpital La Pitié-Salpêtrière
Paris, 75013, France
NCT Number: NCT06066736
Ventilator-associated pneumonia (VAP) is a frequent and serious complication in the ICU, defined by the development of a lung infection in patients ventilated for more than 48 hours. The incidence rate of this condition exceeds 18 episodes per 1000 days of mechanical ventilation in Europe. This nosocomial infection is associated with the highest mortality, ranging from 24% to 76% depending on the series. Reducing the incidence of VAP remains a challenge for clinicians, as evidenced by the many recent recommendations that have led to "bundles" to prevent the onset of this complication. Despite this, these recommendations do not propose a strategy to prevent the recurrence of PAVM, a frequent entity with a reported incidence of 25-35% and a non-consensual definition that increases antibiotic consumption, duration of mechanical ventilation and length of stay in the ICU .
In fact, these recurrences can be linked to:
* Intrinsic patient risk factors (immunosuppression, severity of disease, major inflammatory response, reason for initial admission), * Inappropriate initial antibiotic therapy (type, duration and dose administered), * Characteristics specific to the pathogens encountered (virulence factors or resistance), * Intercurrent complications during management of the initial pneumonia (ARDS, abscess, pleural empyema).
Given the frequency of these recurrences, and the persistent doubts about the role of terrain and pathogen characteristics in their genesis, it seems appropriate to look at risk factors that could help anticipate these events.
The aim of our study will be to identify the risk factors and mortality associated with the occurrence of a recurrence of VAP in patients hospitalized in the intensive care unit.
An essential first step in this work will be to identify and then use the most consensual definition of recurrence of VAP, encompassing recurrence, persistence and superinfection. We will use the definitions in the protocol for the ASPIC trial, which is currently undergoing enrolment.
The second step is to identify risk factors for recurrence. By identifying these factors, it could be possible to propose a prognostic score that would enable careful monitoring (or modification of antibiotic therapy) of patients most at risk of recurrence. Such a score could then be evaluated in a prospective study.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Paris, 75013, France
Ventilator-associated pneumonia (VAP) is a frequent and serious complication in the ICU, defined by the development of a lung infection in patients ventilated for more than 48 hours. The incidence rate of this condition exceeds 18 episodes per 1000 days of mechanical ventilation in Europe. This nosocomial infection is associated with the highest mortality, ranging from 24% to 76% depending on the series. Reducing the incidence of VAP remains a challenge for clinicians, as evidenced by the many recent recommendations that have led to "bundles" to prevent the onset of this complication. Despite this, these recommendations do not propose a strategy to prevent the recurrence of PAVM, a frequent entity with a reported incidence of 25-35% and a non-consensual definition that increases antibiotic consumption, duration of mechanical ventilation and length of stay in the ICU (1,2).
In fact, these recurrences can be linked to:
Given the frequency of these recurrences, and the persistent doubts about the role of terrain and pathogen characteristics in their genesis, it seems appropriate to look at risk factors that could help anticipate these events.
The aim of our study will be to identify the risk factors and mortality associated with the occurrence of a recurrence of VAP in patients hospitalized in the intensive care unit.
An essential first step in this work will be to identify and then use the most consensual definition of recurrence of VAP, encompassing recurrence, persistence and superinfection. We will use the definitions in the protocol for the ASPIC trial (3), which is currently undergoing enrolment.
The second step is to identify risk factors for recurrence. By identifying these factors, it could be possible to propose a prognostic score that would enable careful monitoring (or modification of antibiotic therapy) of patients most at risk of recurrence. Such a score could then be evaluated in a prospective study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention, observational group
Time frame: 28 days after ICU admission
Mortality at 28 days, verify if patient died 28 days after Ventilator-associated pneumonia
Time frame: During inclusion period (from 01JAN2021 to 31DEC2022)
Number of Ventilator-associated pneumonia recurrences during ICU stay
Time frame: 28 days after ICU admission
Number of days without mechanical ventilation at day 28
Time frame: 28 days after ICU admission
Number of days without renal replacement therapy at day 28
Time frame: 28 days after ICU admission
Number of days without catecholamines at day 28
Time frame: 28 days after ICU admission
Number of days without antibiotics at day 28
Time frame: During ICU stay
multiresistant bacteriaacquisition rate
Time frame: During inclusion period (from 01JAN2021 to 31DEC2022)
Length of stay in intensive care unit
Time frame: During inclusion period (from 01JAN2021 to 31DEC2022)
Length of hospital stay
Time frame: During inclusion period (from 01JAN2021 to 31DEC2022)
Number of persistent Ventilator-associated pneumonia
Time frame: During inclusion period (from 01JAN2021 to 31DEC2022)
Number of superinfections of Ventilator-associated pneumonia
Société Française d'Anesthésie et de Réanimation
Other
Acronym: REVAP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07482007
Cross Infection, Disease Attributes
Tanta, Egypt
View Trial DetailsNCT07013032
Cross Infection, Disease Attributes
Konya, Karatay, Turkey (Türkiye)
View Trial DetailsNCT07509697
Artificial Intelligence (AI), Bacterial Infections
Yenimahalle, Ankara, Turkey (Türkiye)
View Trial DetailsNCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial Details